Verification evidence is still being completed.
PDF / print export
InnoMedica Holding AG
Bern, Switzerland
- Verified lead
- Peter Halbherr
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chairman and General Manager
- 2026 technical specialization
- Liposomal Nanomedicine, Talineuren and Talidox, and Swiss Clinical Trials
- Review cycle
- 24 April 2026
- Full address
- Bern, Switzerland (registered seat in Zug)
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- The Org organization chart naming Peter Halbherr as Chairman and General Manager of InnoMedica.
- Editorial note
- Bern nanomedicine biotech with named chairman and general manager, Marly process development, and Swiss clinical programs in breast cancer and Parkinson's disease.
Liposomal Nanomedicine, Talineuren and Talidox, and Swiss Clinical Trials
North Data CHE registry record, Swiss Biotech Association listing, Swiss clinical-trial documentation
Bern nanomedicine biotech with named chairman and general manager, Marly process development, and Swiss clinical programs in breast cancer and Parkinson's disease.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Bern, Switzerland
InnoMedica Holding AG
Liposomal Nanomedicine, Talineuren and Talidox, and Swiss Clinical Trials · Clinical-stage liposomal therapeutics
Bern nanomedicine biotech with named chairman and general manager, Marly process development, and Swiss clinical programs in breast cancer and Parkinson's disease.
- Lead
- Peter Halbherr (verified ↗)
- Address
- Bern, Switzerland (registered seat in Zug) (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage liposomal therapeutics
- Capabilities
- Liposomal Drug-Delivery Platform · Oncology and Neurodegenerative Programs · Swiss Clinical Trial Operations
- Founded
- 2007
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Peter Halbherr
Chairman and General Manager
Full addressBern, Switzerland (registered seat in Zug)
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
North Data Swiss registry record for InnoMedica Holding AG with Zug registered seat.
Open sourceClinical-stage liposomal therapeutics
Bern, Switzerland. Liposomal Nanomedicine, Talineuren and Talidox, and Swiss Clinical Trials. Review completed on 24 Apr 2026.
Swissmedic, EMA, and FDA for clinical oversight
North Data CHE registry record, Swiss Biotech Association listing, Swiss clinical-trial documentation
Liposomal Nanomedicine, Talineuren and Talidox, and Swiss Clinical Trials
Bern nanomedicine biotech with named chairman and general manager, Marly process development, and Swiss clinical programs in breast cancer and Parkinson's disease.
Editorial note
InnoMedica is a Bern-based nanomedicine biotech with a named chairman and general manager, a liposomal technology platform, and Marly Innovation Center process development for oncology and neurodegenerative indications.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Liposomal Drug-Delivery Platform
Oncology and Neurodegenerative Programs
Swiss Clinical Trial Operations
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Liposomal formulation platform
Marly Innovation Center process development
Swiss clinical trial operations
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is InnoMedica Holding AG located?
- InnoMedica Holding AG operates from Bern, Switzerland (registered seat in Zug), Bern, Switzerland.
- Who runs InnoMedica Holding AG?
- InnoMedica Holding AG is led by Peter Halbherr, Chairman and General Manager. Verified 24 Apr 2026.
- What does InnoMedica Holding AG do?
- Bern nanomedicine biotech with named chairman and general manager, Marly process development, and Swiss clinical programs in breast cancer and Parkinson's disease. Core capabilities: Liposomal Drug-Delivery Platform, Oncology and Neurodegenerative Programs, Swiss Clinical Trial Operations.
Editorial context
Related technical briefs
Briefs that name Bern as a covered market or city.